Sozinibercept  (Synonyms: OPT 302; VGX-300)

Sozinibercept (OPT 302; VGX-300) is a soluble form of VEGFR-3, potently inhibits the activity of VEGF-C/D, which are the proangiogenic factors, inhibiting angiogenesis and vascular leakage. Sozinibercept also inhibits diabetic retinal edema in rats^[1][2][3].

VEGF-C/D^[1][2][3]

Sozinibercept inhibits CNV lesion formation and vascular leakage in the mouse laser-induced model of choroidal neovascularization (CNV). Moreover, Sozinibercept exhibits comparable efficacy to Aflibercept (HY-108801; Eylea^®) in CNV mouse model^[1][2].
Sozinibercept (intravitreal injection; once every 4 wk for 4 months) shows selective inhibition of VEGF-C/D, and inhibits diabetic retinal edema induced by streptozotocin (STZ) in the rat model, and equivalent to inhibition of VEGF-A inhibitor (Aflibercept)^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

120.85 kDa

2568358-31-4

Liquid

Colorless to light yellow

[Sozinibercept]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  [FLT4 (fms related receptor tyrosine kinase 4, vascular endothelial growth factor receptor 3, VEGFR3, PCL, VEGFR-3)fragment (1-305, containing the immunoglobulin-like C2-type domains 1, 2 and 3)]2-IGHG1 Fc (Fragment constant)

• [1]. Lashkari K, et al. VGX-300, a ‘Trap’for VEGF-C and VEGF-D, Inhibits Choroidal Neovascularization and Vascular Leakage in a Mouse Model of Wet AMD[J]. Investigative Ophthalmology & Visual Science, 2015, 56(7): 4802-4802.

  [2]. Lashkari K, et al. VEGF-C and VEGF-D Blockade by VGX-300 Inhibits Choroidal Neovascularization and Leakage in a Mouse Model of wet AMD[J]. Investigative Ophthalmology & Visual Science, 2014, 55(13): 1823-1823.

  [3]. Turunen T, et al. VEGF-C and VEGF-D Inhibition by VGX-300 Effectively Reduces Leukocyte Adhesion and Vascular Leakage in the STZ-Rat Model of Diabetic Retinal Edema[J]. Investigative Ophthalmology & Visual Science, 2019, 60(9): 3667-3667.